U.S. Physical Therapy, Inc. (USPH)
| Market Cap | 1.24B +1.8% |
| Revenue (ttm) | 804.27M +11.4% |
| Net Income | 2.66M -15.6% |
| EPS | 0.18 -92.3% |
| Shares Out | 14.92M |
| PE Ratio | 476.93 |
| Forward PE | 27.66 |
| Dividend | $1.84 (2.20%) |
| Ex-Dividend Date | Aug 21, 2026 |
| Volume | 102,666 |
| Open | 81.48 |
| Previous Close | 81.75 |
| Day's Range | 79.01 - 84.08 |
| 52-Week Range | 58.19 - 93.50 |
| Beta | 1.13 |
| Analysts | Buy |
| Price Target | 95.00 (+14.06%) |
| Earnings Date | Nov 4, 2026 |
About USPH
U.S. Physical Therapy, Inc., together with its subsidiaries, operates and manages outpatient physical therapy clinics. It operates through two segments, Physical Therapy Operations and Industrial Injury Prevention Services. The company provides pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. It offers industrial injury prevention services, including onsite injury prevention and rehabilitation, performance... [Read more]
Financial Performance
In 2025, U.S. Physical Therapy's revenue was $773.34 million, an increase of 16.39% compared to the previous year's $664.43 million. Earnings were $21.57 million, a decrease of -22.20%.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for USPH stock is "Buy." The 12-month stock price target is $95.0, which is an increase of 14.06% from the latest price.
News
U.S. Physical Therapy price target raised to $95 from $90 at JPMorgan
JPMorgan raised the firm’s price target on U.S. Physical Therapy (USPH) to $95 from $90 and keeps an Overweight rating on the shares. The firm updated the company’s model. Published…
U.S. Physical Therapy Presented at the 17th Annual Midwest Ideas Conference
HOUSTON--(BUSINESS WIRE)--U.S. Physical Therapy, Inc. (“USPH” or the “Company”) (NYSE, NYSE Texas: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury p...
U.S. Physical Therapy Transcript: 17th Annual Midwest IDEAS Conference
A unique partnership-driven model and disciplined acquisition strategy have enabled steady growth, with a new 10-year NYU Langone alliance expected to boost patient volumes and margins. The injury prevention division continues to expand, and recent reimbursement trends are turning favorable.
U.S. Physical Therapy appoints Etta as Chief Financial Officer
U.S. Physical Therapy (USPH) announced that Nchacha Etta will serve as the Company’s Executive Vice President and Chief Financial Officer, effective as of September 1, 2026. Jason Curtis, the Company’...
U.S. Physical Therapy Announces CFO
HOUSTON--(BUSINESS WIRE)--U.S. Physical Therapy, Inc. (“USPH” or the “Company”) (NYSE, NYSE Texas: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury p...
U.S. Physical Therapy price target raised to $98 from $90 at Barrington
Barrington raised the firm’s price target on U.S. Physical Therapy (USPH) to $98 from $90 and keeps an Outperform rating on the shares, citing increasing confidence regarding FY27 and beyond…
U.S. Physical Therapy Earnings Call Transcript: Q2 2026
Q2 2026 delivered record clinic volumes and strong revenue growth, driven by hospital affiliations and rate increases across payer types. Margins were pressured by higher healthcare costs and pre-hiring, but guidance for 2026 was reaffirmed, with significant margin lift expected as integration completes.
U.S. Physical Therapy Earnings release: Q2 2026
U.S. Physical Therapy released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
U.S. Physical Therapy Quarterly report: Q2 2026
U.S. Physical Therapy has published its Q2 2026 quarterly earnings report on August 6, 2026.
U.S. Physical Therapy Slides: Q2 2026
U.S. Physical Therapy has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
U.S. Physical Therapy reports Q2 adjusted EPS 75c, consensus 84c
Reports Q2 revenue $214.1M, consensus $211.36M. Chris Reading, Chairman and Chief Executive Officer commented, “Our second quarter 2026 results include an important milestone for USPH as we completed ...
U.S. Physical Therapy backs FY26 adjusted EBITDA view $102M-$106M
16:26 EDT U.S. Physical Therapy (USPH) backs FY26 adjusted EBITDA view $102M-$106M
USPH Reports Second Quarter 2026 Results, Reaffirms Full Year Guidance
HOUSTON--(BUSINESS WIRE)--U.S. Physical Therapy, Inc. (“USPH” or the “Company”) (NYSE, NYSE Texas: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury p...
U.S. Physical Therapy, Inc. Schedules Second Quarter 2026 Earnings Release and Conference Call Dates
HOUSTON--(BUSINESS WIRE)--U.S. Physical Therapy, Inc. (“USPH” or the “Company”) (NYSE, NYSE Texas: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury p...
U.S. Physical Therapy acquires twelve-clinic physical therapy practice
U.S. Physical Therapy (USPH) announced the acquisition of a twelve-clinic physical therapy practice, effective July 1, 2026. USPH acquired a 67% equity interest, with 33% retained by the current owner...
U.S. Physical Therapy Announces the Acquisition of a Twelve-Clinic Physical Therapy Practice
HOUSTON--(BUSINESS WIRE)--U.S. Physical Therapy, Inc. (“USPH” or the “Company”) (NYSE, NYSE Texas: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury p...
U.S. Physical Therapy Presented at the BofA Securities 2026 Healthcare Conference
HOUSTON--(BUSINESS WIRE)--U.S. Physical Therapy, Inc. (the “Company”) (NYSE, NYSE Texas: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention ...
U.S. Physical Therapy price target lowered to $90 from $103 at Barrington
Barrington analyst Michael Petusky lowered the firm’s price target on U.S. Physical Therapy (USPH) to $90 from $103 and keeps an Outperform rating on the shares based primarily on “somewhat…
U.S. Physical Therapy price target lowered to $98 from $113 at Citizens
Citizens analyst Constantine Davides lowered the firm’s price target on U.S. Physical Therapy (USPH) to $98 from $113 and keeps an Outperform rating on the shares. Revenue and EBITDA both…
U.S. Physical Therapy Earnings Call Transcript: Q1 2026
Q1 2026 revenue rose 7.9% year-over-year, driven by higher patient volumes and strong commercial rates, despite weather-related disruptions. Guidance for full-year adjusted EBITDA of $102–$106 million was reaffirmed, with hospital partnerships and acquisitions expected to ramp up contributions in the second half.
U.S. Physical Therapy Earnings release: Q1 2026
U.S. Physical Therapy released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
U.S. Physical Therapy Quarterly report: Q1 2026
U.S. Physical Therapy has published its Q1 2026 quarterly earnings report on May 7, 2026.
U.S. Physical Therapy Slides: Q1 2026
U.S. Physical Therapy has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
U.S. Physical Therapy reports Q1 operating EPS 46c, consensus 52c
Reports Q1 revenue $198.3M, consensus $200.94M. Chris Reading, Chairman and Chief Executive Officer commented, “I want to begin by thanking our partners and clinical teams for their tremendous care an...
U.S. Physical Therapy backs FY26 adjusted EBITDA view $102M-$106M
Management reaffirmed the Company’s full year 2026 adjusted EBITDA guidance of $102.0 million to $106.0 million, which includes the partial year impact of two previously announced hospital affiliation...